U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 4 of 4 results

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Oxiperomide was developed as a dopamine-receptor antagonist. Clinical trials have shown that this drug decreased dyskinesia in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Cyclophenazine is an antagonist of dopamine receptors, discovered by Eli Lilly. The drug is claimed to possess tranquilizing, anti-emetic action, and is able to potentiate the action of anticholinergic compounds in inhibiting the gastric secretion.
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Ocaperidone [R 79598] is an equipotent antagonist of central dopamine D2 and serotonin2 receptors being investigated as a potential antipsychotic agent. Ocaperidone is a benzisoxazol piperidine antipsychotic primarily binds and with high affinity to ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Cyclophenazine is an antagonist of dopamine receptors, discovered by Eli Lilly. The drug is claimed to possess tranquilizing, anti-emetic action, and is able to potentiate the action of anticholinergic compounds in inhibiting the gastric secretion.